Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc ACOGF


Primary Symbol: C.ACOG

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Alpha Cognition Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(26)
•••
Post by XeniaTechieon Nov 17, 2021 12:44pm
130 Views
Post# 34136815

Watch the Alpha Cognition presentation from the Q4 Investors

Watch the Alpha Cognition presentation from the Q4 InvestorsAlpha Cognition CEO Michael McFadden presented this morning at the Q4 Investors Summit Group. This was a highly informative session that presented significant lab studies, data and commercialization strategies for their Alpha-1062 treatment which is essentially set to revolutionize the Alzheimer's treatment industry.

Tons of upside potential tapping into the $35B ALZ treatment market where 8/10 patients seek treatment and only 4.5/10 stay in treatments due to side-effects of current treatments, A-1062 is in trials and demonstrating strong improvement in side-effect profiles.

You can view the recording on-demand, here: https://us06web.zoom.us/webinar/register/WN_5oxO1tQORQKs2TZDYxM-yw
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities